angiotensin receptor blocker

angiotensin receptor blocker
Name	Angiotensin receptor blocker
Caption	Structural class illustration
Use	Antihypertensive, cardioprotective, nephroprotective
Discovered	1970s–1990s
Biological target	Angiotensin II type 1 receptor (AT1)
Examples	Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan

angiotensin receptor blocker

Angiotensin receptor blockers are a class of antihypertensive agents used to inhibit the actions of angiotensin II at the angiotensin II type 1 receptor, reducing vasoconstriction and aldosterone-mediated volume expansion. They are prescribed across cardiology and nephrology for hypertension, heart failure, and proteinuric kidney disease, and have been evaluated in major randomized trials and guideline updates by organizations such as the American Heart Association, European Society of Cardiology, and National Institute for Health and Care Excellence.

Medical uses

ARBs are indicated for essential hypertension, heart failure with reduced ejection fraction, and diabetic nephropathy, and are recommended in guideline statements from bodies including the American College of Cardiology, European Society of Hypertension, and Kidney Disease: Improving Global Outcomes. Large outcome trials such as VALIANT (Valsartan Heart Failure Trial), ONTARGET, and IRMA-2 demonstrated impacts on cardiovascular morbidity and renal endpoints in populations represented in studies conducted by institutions like the National Institutes of Health and prominent academic centers such as Mayo Clinic and Cleveland Clinic. Clinicians balance indications against competing recommendations from organizations including the World Health Organization and national regulatory authorities like the U.S. Food and Drug Administration when selecting ARBs for patients with comorbidities such as coronary artery disease managed by teams associated with centers like Massachusetts General Hospital.

Mechanism of action

ARBs selectively block the angiotensin II type 1 (AT1) receptor on vascular smooth muscle, adrenal cortex, and renal cells, preventing angiotensin II–mediated effects first characterized in experiments at institutions such as Harvard Medical School and Johns Hopkins University. This blockade reduces vasoconstriction, sympathetic activation, and aldosterone secretion, mechanisms explored in basic research in laboratories affiliated with Cold Spring Harbor Laboratory and described in reviews published in journals tied to publishers such as The Lancet and The New England Journal of Medicine. Molecular pharmacology of AT1 antagonism was elucidated through structural biology work at facilities including the European Molecular Biology Laboratory and cryo-EM studies associated with investigators from Stanford University.

Pharmacology

Representative ARBs—losartan, valsartan, candesartan, irbesartan, telmisartan—exhibit differences in bioavailability, half-life, metabolic activation, and receptor affinity studied in pharmacokinetic and pharmacodynamic programs at pharmaceutical companies like Merck, Novartis, AstraZeneca, and Boehringer Ingelheim. Losartan is partially converted to an active metabolite via cytochrome P450 enzymes including CYP2C9 and CYP3A4 characterized in metabolomic work at centers such as Scripps Research. Telmisartan shows high lipophilicity and peroxisome proliferator-activated receptor gamma activity noted in translational studies at institutions like University of Cambridge. Dose-ranging and population pharmacology data informing product labels were generated in multi-center trials coordinated with contract research organizations and regulatory submissions to agencies including the European Medicines Agency.

Adverse effects and safety

Common adverse effects include dizziness, hyperkalemia, and renal function changes; serious but less frequent events such as angioedema and fetal toxicity were identified in post-marketing surveillance programs run by agencies like the U.S. Food and Drug Administration and European Medicines Agency. Teratogenicity risk resulted in contraindications in pregnancy codified by professional societies such as the American College of Obstetricians and Gynecologists. Safety signals, including concerns about nitrosamine impurities detected in sartan products, provoked recalls overseen by regulators connected to the World Health Organization and national health authorities, prompting inspections at manufacturing sites operated by global firms like Zhejiang Huahai Pharmaceutical.

Drug interactions

ARBs interact with agents that affect renal perfusion and potassium handling, including potassium-sparing diuretics evaluated in studies from cardiovascular centers such as Brigham and Women's Hospital and combinations involving nonsteroidal anti-inflammatory drugs reviewed by panels at the National Institute for Health and Care Excellence. Cytochrome P450–mediated interactions, especially for agents metabolized by CYP2C9 and CYP3A4, require attention when co-administered with drugs developed by companies like Pfizer and GlaxoSmithKline or with herbal products monitored by pharmacovigilance units at institutions including WHO Collaborating Centres.

History and development

The ARB class emerged from peptide and nonpeptide angiotensin research pursued in industrial laboratories at firms such as DuPont, SmithKline Beecham, and Lilly and academic collaborations with groups at University of California, San Francisco. Early prototypes evolved through medicinal chemistry programs into marketed drugs in the late 1980s and 1990s, with losartan pioneered by teams at DuPont Merck and valsartan developed at Novartis. Landmark regulatory approvals by the U.S. Food and Drug Administration and subsequent inclusion in clinical guidelines codified their adoption across cardiovascular practice in the late 20th and early 21st centuries.

Societal and regulatory aspects

ARBs have been central to public health debates about drug safety, access, and manufacturing quality overseen by bodies such as the World Health Organization, U.S. Food and Drug Administration, and European Medicines Agency. Patent expirations influenced generic competition involving manufacturers like Teva Pharmaceutical Industries and Mylan (Viatris), affecting drug pricing discussed in forums hosted by organizations such as the Organisation for Economic Co-operation and Development and advocacy groups including PatientsLikeMe. International recall events and supply-chain issues prompted legislative and regulatory responses in jurisdictions represented by parliaments such as the United States Congress and European Parliament, shaping ongoing surveillance and quality-control frameworks coordinated with agencies like the International Council for Harmonisation.

Category:Antihypertensive agents